(RTTNews) - Hoth Therapeutics, Inc. (HOTH) Tuesday announced positive preclinical results for HT-KIT, a novel targeted therapy for gastrointestinal stromal tumors (GIST). GIST is a rare but ...

Treatment with pimitespib was associated with stable disease in two-thirds of patients with advanced gastrointestinal stromal ...

Hoth Therapeutics announces positive preclinical results for HT-KIT in aggressive cancer gastrointestinal stromal tumours: New York Wednesday, March 19, 2025, 18:00 Hrs [IST] Hoth ...

RECKGIST score may predict recurrence in neurofibromatosis type 1 GISTs, potentially guiding treatment decisions, according ...

Hoth Therapeutics (HOTH) announced breakthrough preclinical findings demonstrating the efficacy of HT-KIT, a novel targeted ...

A study shows that high-grade glioma tumor cells harboring DNA alterations in the gene PDGFRA responded to the drug avapritinib, which is already approved by the United States Food and Drug ...

A company presentation will take place during the conference's Innovation track on Friday, March 28th at 9:00am. NeauxCancer ...

which is already approved by the United States Food and Drug Administration to treat gastrointestinal stromal tumors ... Genetic Mutations Linked to Toxin Exposure Found in Firefighters' Brain ...

Two new drugs to treat prostate and liver cancer have been given the green light for use by the NHS in Scotland. The Scottish ...

When Jeffrey Lipow went in for a routine endoscopy, it revealed a serious problem. A follow-up endoscopic ultrasound confirmed he had a tumor under ...

Two new medicines have been approved to help treat prostate and liver cancer patients in Scotland. The Scottish Medicines ...